DK2691422T3 - Fremgangsmåder og sammensætninger til cytomegalovirus il-10 protein - Google Patents
Fremgangsmåder og sammensætninger til cytomegalovirus il-10 protein Download PDFInfo
- Publication number
- DK2691422T3 DK2691422T3 DK12764664.4T DK12764664T DK2691422T3 DK 2691422 T3 DK2691422 T3 DK 2691422T3 DK 12764664 T DK12764664 T DK 12764664T DK 2691422 T3 DK2691422 T3 DK 2691422T3
- Authority
- DK
- Denmark
- Prior art keywords
- rhcmvll
- cytomegalovirus
- protein
- rhcmv
- infection
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—DNA viruses
- C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
- C07K16/089—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16161—Methods of inactivation or attenuation
- C12N2710/16162—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (8)
1. Cytomegalovirus IL-10 protein valgt fra: (i) et cytomegalovirus IL-10 protein som vist i SEQ ID NO: 3, eller bestående af aminosyresekvensen MLSVMVSSSLVUVFFLGASEEAKPAATTTTTTTSKNTKPQCRPEDYATRLQDLRV TFHRVKPTLQREDDYSVWLDGTWKGCWGCSVMDWLLRRYLEiVFPAGDHVYPGLKTE LHSMRSTLESSYKDMRGCPLLGCGDKSVISRLSGEAERKSDNGTRKGLSELDTLFSRLEE YLHSRK eller MLSVMVSSSLVUVFFLGASEEAKPATTTfKNTKPGCRPEDYATRLQDLRVTFHRV KPTLQREDDYSVWLDGTWKGCWGGSVMDWLLRRYLEIVFPAGDRVYPGLKTELHSMR STLESfYKDMRGCPLLGCGDKSVISRLSGEAERKSDNGTRKGLSELDTLFSRLEEYLHSR Kl eller MLSVMVSSSLVLIVFFLGA5EEAKPATTTTTIKNTKPQGRPEDYATRLQDLRYTFH RKPTLQREDDYSVWLDGTWKGCWGGSVMDWLLRRYLEIVFPAGDHVYPGLKTELHSM RSTLESIYKOMRQCPLLGCGDKSVISRLSGEAERKSDNGTRKGLSELDTLFSRLEEYLHS RK, eller MLSVMVSSSLVLIVFFLGASEEAKPATTTTKNTKPGCRPEDYATRLGDLRVTFHRV KPTLQREDDYSVWLDGTWKGCWGCSVMDWLLRRYLEIVFPAGDHVYPGLKTELHSMR STLESIYKDMRGCPLLGCGDKSVISRLSQEAERKSDNGTRKGLSEIDTLFSRLEEYLHSR K, eller en homolog deraf med mindst 90 % identitet dermed, kendetegnet ved en aminosyresubstitution ved én eller flere af K58, Q62, E160 og D162, hvor nummereringen er ifølge SEQ ID NO: 3; (ii) et cytomegalovirus IL-10 protein som vist i SEQ ID NO: 1 eller SEQ ID NO: 2 eller en homolog deraf med mindst 90 % identitet dermed, kendetegnet ved en aminosyresubstitution ved én eller flere af R63, Q67, E174 og D176, hvor nummereringen er ifølge SEQ ID NO: 1, fortrinsvis ved en aminosyresubstitution ved én eller flere af Q67R, R63E, E174Q og D176H, mere fortrinsvis ved aminosyresubstitutioner ved Q67R og D176H eller ved aminosyresubstitutioner ved E174Q og D176H, hvor aminosyresubstitutionen(eme) resulterer i en fænotype af reduceret binding til et interleukin-10- (IL-10) receptorprotein og bevaret immunogenicitet sammenlignet med et cytomegalovirus IL-10 protein uden substitution(er).
2. Isoleret nukleinsyremolekyle, der omfatter en nukleotidsekvens, der koder for cytomegalovirus IL-10 protein ifølge krav 1.
3. Vektor, der omfatter nukleinsyremolekylet ifølge krav 2.
4. Sammensætning, der omfatter cytomegalovirus IL-10 proteinet ifølge krav 1, nukleinsyremolekylet ifølge krav 2 eller vektoren ifølge krav 3, i en farmaceutisk acceptabel bærer.
5. Cytomegalovirus IL-10 protein ifølge krav 1, nukleinsyremolekyle ifølge krav 2, vektor ifølge krav 3 og/eller sammensætning ifølge krav 4, i en hvilken som helst kombination, til anvendelse i behandling af en cytomegalovirus-infektion hos individet.
6. Cytomegalovirus IL-10 protein ifølge krav 1, nukleinsyremolekyle ifølge krav 2, vektor ifølge krav 3 og/eller sammensætning ifølge krav 5, i en hvilken som helst kombination, til anvendelse i forebyggelse eller svækkelse af en primær cytomegalovirus-infektion.
7. Cytomegalovirus IL-10 protein ifølge krav 1, nukleinsyremolekyle ifølge krav 2, vektor ifølge krav 3 og/eller sammensætning ifølge krav 4, i en hvilken som helst kombination, til anvendelse i reduktion af risikoen for cytomegalovirus-infektion hos en transplantatmodtager eller til reduktion af risikoen for cytomegalovirus-infektion hos et immunkompromitteret eller immunsupprimeret individ.
8. Neutraliserende antistof, der er specifikt reaktivt mod et cytomegalovirus IL-10 protein valgt fra: (i) et cytomegalovirus IL-10 protein som vist i SEQ ID NO: 3, eller bestående af aminosyresekvensen MLSVMVSSSLVUVFFLGASEEAKPAATTTTTTTIKNTKPQCRPEDYATRLQDLRV TFHRVKPTLQREDDYSVWLDGTWKGCWGCSVMDWLLRRYLESVFPAGDHVYPGLKTE LHSMRSTLESiYKDMRQCPLLGCGDKSVISRLSQEAERKSDNGTRKGLSELDTLFSRLEE YLH3RK eller MLSVMVSSSLVLIVFFLGASEEAKPATTTiKNTKPQCRPEDYATRLQDLRVTFHRV KPTLQREDDYSVWLDGTWKGCWGCSVMDWLLRRYLEiVFPAGDHVYPGLKTELHSMR stlessykdmrqcpllgcgdksvisrlsqeaerksdngtrkglseldtlfsrleeylhsr K: eller MLSVMVSSSLVUVFFLGASEEAKPATTTTTIKNTKPQCRPEDYATRLGDLRVTFHR VKPTLQREDDYSVWLDGTWKGCWGCSVMDWLLRRYLEfVFPAGDHVYPGLKTELHSM RSTLESiYKDMRQCPLLGCGDKSVISRLSQEAERKSDNGTRKGLSELDTLFSRLEEYLHS RK eller MLSVMVSSSLVUVFFLGASEEAKPATTTTKNTKPQCRPEDYATRLQDLRVTFHRV KPTLQREDDYSVWLDGTWKGCWGCSVMDWLLRRYLEIVFPAGDHVYPGLKTELHSMR STLESiYKDMRGCPLLGGGDKSVISRLSQEAERKSDNGTRKGLSELDTLFSRLEEYLHSR K eller en homolog deraf med mindst 90 % identitet dermed, kendetegnet ved en aminosyresubstitution ved én eller flere af K58, Q62, E160 og D162, hvor nummereringen er ifølge SEQ ID NO: 3; (ii) et cytomegalovirus IL-10 protein som vist i SEQ ID NO: 1 eller SEQ ID NO: 2 eller en homolog deraf med mindst 90 % identitet dermed, kendetegnet ved en aminosyresubstitution ved én eller flere af R63, Q67, E174 og D176, hvor nummereringen er ifølge SEQ ID NO: 1, fortrinsvis ved en aminosyresubstitution ved én eller flere af Q67R, R63E, E174Q og D176H, mere fortrinsvis ved aminosyresubstitutioner ved Q67R og D176H eller ved aminosyresubstitutioner ved E174Q og D176H.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161468945P | 2011-03-29 | 2011-03-29 | |
| PCT/US2012/030666 WO2012135177A2 (en) | 2011-03-29 | 2012-03-27 | Methods and compositions for cytomegalovirus il-10 protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2691422T3 true DK2691422T3 (da) | 2019-03-18 |
Family
ID=46932285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12764664.4T DK2691422T3 (da) | 2011-03-29 | 2012-03-27 | Fremgangsmåder og sammensætninger til cytomegalovirus il-10 protein |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9321813B2 (da) |
| EP (1) | EP2691422B1 (da) |
| DK (1) | DK2691422T3 (da) |
| ES (1) | ES2716010T3 (da) |
| WO (1) | WO2012135177A2 (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CN110241137A (zh) * | 2012-07-27 | 2019-09-17 | 希望之城 | 一种递送ul128复合体和预防cmv感染的mva疫苗 |
| WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| WO2016168741A2 (en) * | 2015-04-16 | 2016-10-20 | Spencer Juliet V | Detection of human cytomegalovirus |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| KR102439221B1 (ko) | 2017-12-14 | 2022-09-01 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| EP3762025A4 (en) * | 2018-03-09 | 2021-12-01 | The Regents of the University of California | CMV VECTORS AND USES THEREOF |
| WO2020037043A1 (en) * | 2018-08-15 | 2020-02-20 | The Regents Of The University Of California | Il-10 inhibition for vaccines and immunotherapy |
| CN112955546B (zh) * | 2018-11-26 | 2024-04-16 | 江苏恒瑞医药股份有限公司 | 一种人白细胞介素10变体及其衍生物 |
| WO2020108735A1 (en) | 2018-11-26 | 2020-06-04 | Blink Biomedical Sas | Antibodies to cytomegalovirus interleukin-10 |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2138997C (en) | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
-
2012
- 2012-03-27 DK DK12764664.4T patent/DK2691422T3/da active
- 2012-03-27 US US14/008,484 patent/US9321813B2/en not_active Expired - Fee Related
- 2012-03-27 ES ES12764664T patent/ES2716010T3/es active Active
- 2012-03-27 EP EP12764664.4A patent/EP2691422B1/en not_active Not-in-force
- 2012-03-27 WO PCT/US2012/030666 patent/WO2012135177A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP2691422A4 (en) | 2014-12-17 |
| WO2012135177A2 (en) | 2012-10-04 |
| US20140099299A1 (en) | 2014-04-10 |
| US9321813B2 (en) | 2016-04-26 |
| EP2691422B1 (en) | 2019-02-06 |
| EP2691422A2 (en) | 2014-02-05 |
| ES2716010T3 (es) | 2019-06-07 |
| WO2012135177A3 (en) | 2013-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2691422T3 (da) | Fremgangsmåder og sammensætninger til cytomegalovirus il-10 protein | |
| RU2720614C9 (ru) | Иммунобиологическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты) | |
| Gerna et al. | Human cytomegalovirus (HCMV) infection/re-infection: development of a protective HCMV vaccine | |
| US7976845B2 (en) | Human cytomegalovirus immunotherapy | |
| JP2021121185A (ja) | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 | |
| US10300129B2 (en) | Epstein-Barr-virus vaccine | |
| WO2021076010A1 (en) | Pharmaceutical agent for inducing specific immunity against sars-cov-2 | |
| US20240226291A9 (en) | Combination of novel vaccines against zika virus and dna antibody constructs for use against zika virus | |
| Reap et al. | Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus | |
| EP1799255A1 (en) | Recombinant human cytomegalovirus and vaccines comprising heterologous antigens | |
| Chang et al. | Subunit vaccines with a saponin-based adjuvant boost humoral and cellular immunity to MERS coronavirus | |
| Logsdon et al. | Design and analysis of rhesus cytomegalovirus IL-10 mutants as a model for novel vaccines against human cytomegalovirus | |
| US11806395B2 (en) | Epstein-Barr virus-like particles with broadened antigenic spectrum | |
| Pereira et al. | Enhanced immune responses and protective immunity to zika virus induced by a DNA vaccine encoding a chimeric NS1 fused with type 1 herpes virus gD protein | |
| US20250325657A1 (en) | Modified vaccinia ankara (mva) vaccine | |
| Rigato et al. | Immunization of neonatal mice with LAMP/p55 HIV gag DNA elicits robust immune responses that last to adulthood | |
| RU2849759C1 (ru) | Иммунобиологическое средство для индукции специфического иммунного ответа против вируса Западного Нила и его применение | |
| US20220226466A1 (en) | Pharmaceutical agent for inducing specific immunity against sars-cov-2 | |
| US20250332249A1 (en) | Cytomegalovirus t cell epitopes and uses thereof | |
| Azadfar et al. | Evaluation of Heterologous Prime-boost Vaccine Strategy Using Full-length Cytomegalovirus Glycoprotein B to Trigger BALB/c Mice Immunity | |
| US20230173061A1 (en) | Human cytomegalovirus polyepitope vaccine composition | |
| Eberhardt | Evaluation of Viral Modulating Protein Rhesus Cytomegalovirus Interleukin-10 Ortholog as a Vaccine Candidate for Cytomegalovirus Infection | |
| Cicin-Sain et al. | MCMV based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination | |
| Schleiss | Cytomegalovirus vaccines in the pipeline | |
| AU2012227280A1 (en) | Human cytomegalovirus immunotherapy |